Neuropsychiatric disorders in cushing's syndrome

Frontiers in Neuroscience

Volumn 9, Issue MAR, 2015, Pages

  Pivonello, Rosario ^a   Simeoli, Chiara ^a   De Martino, Maria Cristina ^a   Cozzolino, Alessia ^a   De Leo, Monica ^a   Iacuaniello, Davide ^a   Pivonello, Claudia ^a   Negri, Mariarosaria ^a   Pellecchia, Mariateresa ^b   Iasevoli, Felice ^c   Colao, Annamaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cognitive impairment; Cushing's syndrome; Neurological disorders; Psychiatric disorders; Quality of life

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLUCOCORTICOID; HYDROCORTISONE; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; NERVE GROWTH FACTOR BETA SUBUNIT; NEUROLEPTIC AGENT;

ANXIETY DISORDER; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CARDIOVASCULAR RISK; COGNITIVE DEFECT; CUSHING SYNDROME; DECREASED APPETITE; DENTATE GYRUS; DEPRESSIVE PSYCHOSIS; DISEASE ASSOCIATION; DISEASE COURSE; EMOTIONAL DISORDER; FAMILY LIFE; HIPPOCAMPUS; HOPELESSNESS; HORMONE RELEASE; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERCORTISOLISM; HYPOPHYSIS TUMOR; JOB PERFORMANCE; LIBIDO DISORDER; MAJOR DEPRESSION; MANIA; MENTAL DISEASE; NERVOUS SYSTEM DEVELOPMENT; PANIC; PREVALENCE; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL WELL BEING; PSYCHOSOCIAL WITHDRAWAL; QUALITY OF LIFE; REMISSION; SLEEP DISORDER; SOCIAL ADAPTATION; SOCIAL ASPECT; SUICIDAL IDEATION; SUICIDE ATTEMPT; THERAPY EFFECT; WEIGHT GAIN;

EID: 84928111814     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2015.00129     Document Type: Article

References (64)

1. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP et al. (2003) Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 88(12):5593-602.
2. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. (2006) Cushing's syndrome. Lancet; 367:1605-17
3. Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A. (2008) Cushing's Syndrome. Endocrinol Metab Clin North Am. 37(1):135-49, ix. Review.
4. Pivonello R, De Leo M, Vitale P, Cozzolino A, Simeoli C, De Martino MC, et al. (2010) Pathophysiology of diabetes mellitus in Cushing's syndrome. Neuroendocrinology; 92 Suppl 1:77-81. Review.
5. Pivonello R, Faggiano A, Lombardi G, Colao A. (2005) The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin North Am. 34(2):327-39, VIII.
6. De Leo M, Pivonello R, Auriemma RS, Cozzolino A, Vitale P, Simeoli C, et al. (2010) Cardiovascular disease in Cushing's syndrome: heart versus vasculature. Neuroendocrinology; 92 Suppl 1:50-4. Review.
7. Van der Pas R, Leebeek FW, Hofland LJ, de Herder WW, Feelders RA. (2013) Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment. Clin Endocrinol (Oxf). 78(4):481-8. Review.
8. Tauchmanovà L, Pivonello R, Di Somma C, Rossi R, De Martino MC, Camera L, et al. (2006) Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab. 91(5):1779-84.
9. Pereira AM, Tiemensma J, Romijn JA. (2010) Neuropsychiatric disorders in Cushing's syndrome. Neuroendocrinology 92 Suppl 1:65-70. Epub 2010 Sep 10. Review.
10. Gotch PM. (1994) Cushing's syndrome from the patient's perspective. Endocrinol Metab Clin North Am. 23(3):607-617
11. Webb SM, Badia X, Barahona MJ, Colao A, Strasburger CJ, Tabarin A, et al. (2008) Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. Eur J Endocrinol 158(5): 623-630
12. Clayton R.N. (2010) Mortality and morbidity in Cushing's disease. Neuroendocrinology; 92(suppl 1): 71-76.
13. Cushing H. (1932) The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 50: 137-95
14. Sonino N, Fava GA. (2001) Psychiatric disorders associated with Cushing's syndrome. Epidemiology, pathophysiology and treatment. CNS Drugs 15:361-373
15. Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW, Chrousos GP. (1997) The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism. J Clin Endocrinol Metab 82(3): 912-919
16. Sonino N, Fallo F, Fava GA. (2010) Psychosomatic aspects of Cushing's syndrome. Rev Endocr Metab Disord 11(2): 95-104
17. De Kloet ER, Vreugdenhil E, Oitzl MS, Joëls M. (1998) Brain corticosteroid receptor balance in health and disease. Endocr Rev. 19(3):269-301. Review.
18. Patil CG, Lad SP, Katznelson L, Laws ER Jr. (2007) Brain atrophy and cognitive deficits in Cushing's disease. Neurosurg Focus 23(3): E11
19. Simmons NE, Do HM, Lipper MH, Laws ER Jr. (2000) Cerebral atrophy in Cushing's disease. Surg Neurol. 53(1):72-6.
20. Bourdeau I, Bard C, Noël B, Leclerc I, Cordeau MP, Bélair M, et al. (2002) Loss of brain volume in endogenous Cushing's syndrome and its reversibility after correction of hypercortisolism. J Clin Endocrinol Metab 87(5): 1949-1954
21. Michaud K, Forget H, Cohen H. (2009) Chronic glucocorticoid hypersecretion in Cushing's syndrome exacerbates cognitive aging. Brain Cogn 71(1): 1-8
22. Jacobs BL, van Praag H, Gage FH. (2000) Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry 5: 262-9
23. Sonino N, Fava GA, Raffi AR, Boscaro M, Fallo F. (1998) Clinical correlates of major depression in Cushing's disease. Psychopathology 31(6): 302-306
24. Haskett RF. (1985) Diagnostic categorization of psychiatric disturbance in Cushing's syndrome. Am J Psychiatry 142(8):911-916
25. Hudson JI, Hudson MS, Griffing GT, Melby JC, Pope HG Jr. (1987) Phenomenology and family history of affective disorder in Cushing's disease. Am J Psychiatry. 144(7): 951-953
26. Loosen PT, Chambliss B, DeBold CR, Shelton R, Orth DN. (1992) Psychiatric phenomenology in Cushing's disease. Pharmacopsychiatry 25(4): 192-198
27. Sonino N, Fava GA, Belluardo P, Girelli ME, Boscaro M. (1993) Course of depression in Cushing's syndrome: response to treatment and comparison with Graves' disease. Horm. Res. 39(5- 6): 202-206
28. Kelly WF. (1996) Psychiatric aspects of Cushing's syndrome QJ Med 89(7):543-551
29. Dorn LD, Burgess ES, Dubbert B, Simpson SE, Friedman T, Kling M, et al. (1995) Psychopathology in patients with endogenous Cushing's syndrome: 'atypical' or melancholic features. Clin Endocrinol (Oxf) 43(4): 433-442
30. Starkman MN. (2013) Neuropsychiatric findings in Cushing's syndrome and exogenous glucocorticoid administration Endocrinol Metab Clin N Am 42(3): 477-488
31. Starkman MN, Schteingart DE, Schork MA. (1981) Depressed mood and other psychiatric manifestations of Cushing's syndrome: relationship to hormone levels. Psychosom Med 43(1): 3-18
32. Whelan TB, Schteingart DE, Starkman MN, Smith A. (1980) Neuropsychological deficits in Cushing's Syndrome J Nerv Ment Dis 168 (12):753-7
33. Pivonello R, De Martino MC, De Leo M, Tauchmanovà L, Faggiano A, Lombardi G, Colao A. (2007) Cushing's syndrome: aftermath of the cure. Arq Bras Endocrinol Metabol. 51(8):1381-91. Review.
34. Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di Somma C, et al. (2003) Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab. 88(6):2527-33.
35. Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, et al. (1999) Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab. 84(8):2664-72.
36. Faggiano A, Pivonello R, Filippella M, Di Somma C, Orio F Jr, Lombardi G, Colao A. (2001) Spine abnormalities and damage in patients cured from Cushing's disease. Pituitary 4(3):153-61.
37. Colao A, Cozzolino A, Pivonello R (2012) Quality of life in patients with Cushing's disease: a modern approach. Clin Endocrinol (Oxf) 76(6): 776-777
38. Jeffcoate WJ, Silverstone JT, Edwards CR, Besser GM. (1979) Psychiatric manifestations of Cushing's syndrome: response to lowering of plasma cortisol. Q J Med, 48: 465-72
39. Starkman MN, Schteingart DE, Schork MA. (1986) Cushing's syndrome after treatment: changes in cortisol and ACTH levels, and amelioration of the depressive syndrome. Psychiatry Res; 19(3): 177-8
40. Kramlinger KG, Peterson GC, Watson PK, Leonard LL. (1985) Metyrapone for depression and delirium secondary to Cushing's syndrome. Psychosomatics; 26 (1): 67-71
41. Cohen SI. (1980) Cushing's syndrome: a psychiatric study of 29 patients. Br J Psychiatry; 136: 120-4
42. Van der Lely AJ, Foeken K, van der Mast RC, Lamberts SW. (1991) Rapid reversal of acute psychosis in the Cushing's syndrome with the cortisol-receptor antagonist mifepristone (RU 486). Ann Intern Med; 114(2): 143-4
43. Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB, et al. (1991) Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin. Endocrinol. (Oxf.) 35: 169-178
44. Kelly WF, Kelly MJ, Faragher B. (1996) A prospective study of psychiatric and psychological aspects of Cushing's syndrome. Clin Endocrinol; 45(6): 715-720
45. Wolkowitz OM, Reus VI. (1999) Treatment of depression with antiglucocorticoid drugs. Psychosom Med. 61(5): 698-711
46. Hirsch D, Orr G, Kantarovich V, Hermesh H, Stern E, Blum I. (2000) Cushing's syndrome presenting as a schizophrenia-like psychotic state. Isr. J. Psychiatry Relat. Sci. 37(1): 46-50
47. Howland RH. (2013) Mifepristone as a therapeutic agent in psychiatry. J Psychosoc Nurs Ment Health Serv. 51(6):11-4. Review
48. Dorn LD, Cerrone P. (2000) Cognitive function in patients with Cushing syndrome: a longitudinal perspective. Clin. Nurs. Res. 9(4): 420-440
49. Forget H, Lacroix A, Cohen H. (2002) Persistent cognitive impairment following surgical treatment of Cushing's syndrome. Psychoneuroendocrinology 27(3): 367-383
50. Heald AH, Ghosh S, Bray S, Gibson C, Anderson SG, Buckler H, Fowler HL. (2004) Long term negative impact on quality of life in patients with successfully treated Cushing's disease. Clin. Endocrinol. (Oxf.) 61(4): 458- 465
51. Merke DP, Giedd JN, Keil MF, Mehlinger SL, Wiggs EA, Holzer S et al. (2005) Children experience cognitive decline despite reversal of brain atrophy one year after resolution of Cushing syndrome. J. Clin. Endocrinol. Metab. 90(5): 2531-2536
52. Tiemensma J, Kokshoorn NE, Biermasz NR, Keijser BJ, Wassenaar MJ, Middelkoop HA et al. (2010) Subtle cognitive impairments in patients with long-term cure of Cushing's disease. J Clin Endocrinol Metab; 95(6):2699-2714
53. Maheu FS, Mazzone L, Merke DP, Keil MF, Stratakis CA, Pine DS, Ernst M. (2008) Altered amygdala and hippocampus function in adolescents with hypercortisolemia: a functional magnetic resonance imaging study of Cushing's syndrome. Dev Psychopathol.; 20(4): 1177-1189
54. Ragnarsson O, Berglund P, Eder DN, Johannsson G. (2012) Long-term cognitive impairments and attentional deficits in patients with Cushing's disease and cortisol-producing adrenal adenoma in remission. J Clin Endocrinol Metab. 97(9) E1640-8
55. Ragnarsson O, Johannsson G. (2013) Cushing's syndrome: a structured short- and long-term management plan for patients in remission. European Journal of Endocrinology 169(5) R139-R152
56. Resmini E, Santos A, Gómez-Anson B, Vives Y, Pires P, Crespo I, et al. (2012) Verbal and visual memory performance and hippocampal volumes, measured by 3-Tesla magnetic resonance imaging, in patients with Cushing's syndrome. J Clin Endocrinol Metab 97(2): 663-671
57. Bourdeau I, Bard C, Noël B, Leclerc I, Cordeau MP, Bélair M et al. (2002) Loss of Brain Volume in Endogenous Cushing's Syndrome and Its Reversibility after Correction of Hypercortisolism J Clin Endocrinol Metab. 87(5):1949-1954
58. Resmini E, Santos A, Gómez-Anson B, López-Mourelo O, Pires P, Vives-Gilabert Y, et al. (2013) Hippocampal dysfunction in cured Cushing's syndrome patients, detected by (1) H-MR spectroscopy. Clinical Endocrinology 79(5): 700-707
59. Valassi E, Santos A, Yaneva M, Tóth M, Strasburger CJ, Chanson P, et al. (2011) The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol, 165(3): 383-92
60. Lindsay JR, Nansel T, Baid S, Gumowski J, Nieman LK. (2006) Long term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission. J Clin Endocrinol Metab.91(2):447-53
61. Wagenmakers MA, Netea-Maier RT, Prins JB, Dekkers T, den Heijer M, Hermus AR. (2012) Impaired quality of life in patients in long-term remission of Cushing's syndrome of both adrenal and pituitary origin: a remaining effect of long-standing hypercortisolism? European Journal of Endocrinology 167(5): 687-695
62. Sonino N, Bonnini S, Fallo F, Boscaro M, Fava GA. (2006) Personality characteristics and quality of life in patients treated for Cushing's syndrome. Clin Endocrinol. 64(3):314-8
63. Van Aken MO, Pereira AM, Biermasz NR, van Thiel SW, Hoftijzer HC, Smit JW, et al. (2005) Quality of Life in Patients after Long-Term Biochemical Cure of Cushing's Disease. J Clin Endocrinol Metab. 90(6):3279-3286
64. Keil MF, Merke DP, Gandhi R, Wiggs EA, Obunse K, Stratakis CA. (2009) Quality of life in children and adolescents one-year after cure of Cushing syndrome: a prospective study Clin Endocrinol 71(3): 326-333